Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis
- PMID: 27733315
- DOI: 10.1016/s1499-3872(16)60135-2
Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis
Abstract
Background: The liver, as the main iron storage compartment and the place of hepcidin synthesis, is the central organ involved in maintaining iron homeostasis in the body. Excessive accumulation of iron is an important risk factor in liver disease progression to cirrhosis and hepatocellular carcinoma. Here, we review the literature on the molecular pathogenesis of iron overload and its clinical consequences in chronic liver diseases.
Data sources: PubMed was searched for English-language articles on molecular genesis of primary and secondary iron overload, as well as on their association with liver disease progression. We have also included literature on adjuvant therapeutic interventions aiming to alleviate detrimental effects of excessive body iron load in liver cirrhosis.
Results: Excess of free, unbound iron induces oxidative stress, increases cell sensitivity to other detrimental factors, and can directly affect cellular signaling pathways, resulting in accelerated liver disease progression. Diagnosis of liver cirrhosis is, in turn, often associated with the identification of a pathological accumulation of iron, even in the absence of genetic background of hereditary hemochromatosis. Iron depletion and adjuvant therapy with antioxidants are shown to cause significant improvement of liver functions in patients with iron overload. Phlebotomy can have beneficial effects on liver histology in patients with excessive iron accumulation combined with compensated liver cirrhosis of different etiology.
Conclusion: Excessive accumulation of body iron in liver cirrhosis is an important predictor of liver failure and available data suggest that it can be considered as target for adjuvant therapy in this condition.
Similar articles
-
Iron overload in nonalcoholic steatohepatitis.Adv Clin Chem. 2011;55:105-32. doi: 10.1016/b978-0-12-387042-1.00006-x. Adv Clin Chem. 2011. PMID: 22126026 Review.
-
Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis.Gastroenterol Clin Biol. 2010 Jan;34(1):1-7. doi: 10.1016/j.gcb.2009.07.032. Epub 2009 Sep 16. Gastroenterol Clin Biol. 2010. PMID: 19762191 Review.
-
Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload.J Hepatol. 2017 Aug;67(2):360-369. doi: 10.1016/j.jhep.2017.03.012. Epub 2017 Mar 22. J Hepatol. 2017. PMID: 28341391 Free PMC article.
-
Dietary iron overload in the African and hepatocellular carcinoma.Liver Int. 2007 Aug;27(6):735-41. doi: 10.1111/j.1478-3231.2007.01515.x. Liver Int. 2007. PMID: 17617115 Review.
-
Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis.Semin Liver Dis. 2005 Nov;25(4):433-49. doi: 10.1055/s-2005-923315. Semin Liver Dis. 2005. PMID: 16315137 Review.
Cited by
-
Iron as an emerging therapeutic target in critically ill patients.Crit Care. 2023 Dec 4;27(1):475. doi: 10.1186/s13054-023-04759-1. Crit Care. 2023. PMID: 38049866 Free PMC article. Review.
-
Assessing the accuracy of CMRtools software for diagnosing liver iron overload in thalassemia patients: influencing factors and optimisation strategies.Front Med (Lausanne). 2024 Sep 20;11:1424294. doi: 10.3389/fmed.2024.1424294. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39371340 Free PMC article.
-
Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC.Front Physiol. 2018 Feb 6;9:66. doi: 10.3389/fphys.2018.00066. eCollection 2018. Front Physiol. 2018. PMID: 29467672 Free PMC article.
-
Interpreting Iron Homeostasis in Congenital and Acquired Disorders.Pharmaceuticals (Basel). 2023 Feb 21;16(3):329. doi: 10.3390/ph16030329. Pharmaceuticals (Basel). 2023. PMID: 36986429 Free PMC article. Review.
-
Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease.World J Hepatol. 2024 May 27;16(5):671-677. doi: 10.4254/wjh.v16.i5.671. World J Hepatol. 2024. PMID: 38818299 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical